Skip to main content
. 2010 Jun 14;15(7):683–694. doi: 10.1634/theoncologist.2009-0235

Table 3.

Incidence of cardiovascular adverse effects in phase III trials evaluating sorafenib

graphic file with name onc00710-0609-t03.jpg

Abbreviations: bid, twice daily; FDA, Food and Drug Administration; LVEF, left ventricular ejection fraction; NA, not available; NO, not observed; NOS, not otherwise specified.